Pfizer’s Cibinqo and Everest Medicines’ Cefepime-Taniborbactam Selected for Priority Reviews by CDE
The Center for Drug Evaluation (CDE) has indicated on its website that Pfizer’s (NYSE: PFE)...
AbbVie
AbbVie’s Allergan Aesthetics Secures NMPA Approval for Juvéderm VOLUMA with Lidocaine
Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has announced that it has received marketing...
AbbVie’s Skyrizi Outperforms Janssen’s Stelara in Phase III Crohn’s Disease Trial
AbbVie (NYSE: ABBV) has announced early data from a Phase III trial that compared the...
EMA and FDA Review AbbVie’s Skyrizi for Ulcerative Colitis Indication Extension
The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have accepted...
Cordavis Launches First Biosimilar: Novartis’ Hyrimoz to Compete with Humira
Swiss pharmaceutical giant Novartis (NYSE: NVS) unit Sandoz’s biosimilar product, Hyrimoz (adalimumab), which references AbbVie’s...
European Commission Approves AbbVie’s Aquipta for Migraine Prevention in Adults
The European Commission (EC) has granted marketing approval to AbbVie (NYSE: ABBV) for its drug...
GuangDong Pharmaceutical Association Releases Updated Off-Label Drug List for 2023
The GuangDong Pharmaceutical Association has released the 2023 version of its off-label drug list, marking...
Mabwell Secures Licensing Deal with Morocco’s Sothema for Biosimilar Humira
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced a significant licensing and commercialization...
AbbVie and Calibr Announce Strategic Collaboration to Advance Preclinical Research
AbbVie (NYSE: ABBV) and US-based Calibr, the nonprofit drug discovery division of San Diego research...
AbbVie’s Aquipta and Novartis’s Piqray Receive Regulatory Approvals in Mexico
Mexico’s Federal Commission for Protection against Health Risks (COFEPRIS) has granted registration approvals to two...
Major Pharma Companies Pledge Support for 250,000 Genomes Sequencing Project
This week, leading pharmaceutical companies AbbVie (NYSE: ABBV), Amgen (NASDAQ: AMGN), AstraZeneca (AZ; NASDAQ: AZN),...
Chile Expands Financial Coverage for AbbVie’s RSV Prophylaxis Synagis
Chile’s Ministry of Health (MINSAL) has announced an immediate expansion in the coverage under its...
Harbour BioMed Reports First-Ever Profit in H1 2023 Interim Financial Results
Harbour BioMed (HKG: 2142), a biotech company with operations in Suzhou, China, Cambridge in the...
AbbVie’s Rinvoq Receives NMPA Approval for Moderate to Severe Crohn’s Disease Treatment
US pharmaceutical firm AbbVie (NYSE: ABBV) has announced receiving market approval from the National Medical...
Jacobio Pharma Retakes Global Rights to SHP2 Inhibitors After Terminating AbbVie Agreement
China-based Jacobio Pharma (HKG: 1167) has announced the cancellation of a licensing agreement with US...
Sinocelltech Group Launches Biosimilar Version of AbbVie’s Humira in China
China-based Sinocelltech Group Ltd (SHA: 688520) has officially commercialized its biosimilar version of AbbVie’s (NYSE:...
AbbVie Inc. Files Lawsuit Against BeiGene Over BTK Inhibitor Brukinsa
US-based AbbVie Inc., (NYSE: ABBV), the company behind the first-in-class Bruton’s tyrosine kinase (BTK) inhibitor...
Sinocelltech Group Receives NMPA Approval for Biosimilar Version of Humira
China-based Sinocelltech Group Ltd (SHA: 688520) has announced that it has received market approval from...
Q1 2023 financial report: AstraZeneca leads innovation in China, Sanofi’s sales in China decline
Several multinational companies (MNCs) have released their Q1 2023 financials, showing a varied performance over...
AbbVie’s China General Manager Ou Silang Steps Down, Intercon’s Colzi to Take Interim Role
Ou Silang, Vice President and China General Manager of US pharmaceutical major AbbVie (NYSE: ABBV),...